Send Press Release To Your Friends

PR Title:	Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies that support public health goals
PR Summary:	Novartis announced today that it received regulatory approval in China from the State Food and Drug Administration (SFDA) for Lucentis® (ranibizumab) to treat wet (neovascular) age-related macular degeneration (AMD), and is launching Galvus® (vildagliptin), an oral treatment for patients with type 2 diabetes approved in China as an add-on to metformin, the standard of care[3],[4] .

	Basic Information
	Your Name* Your Email* Friend's Name Friend's Email 1* 2   3   Your Message